A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response

Journal of Infectious Diseases

Volumn 214, Issue 6, 2016, Pages 832-835

  Durbin, Anna P ^a   Kirkpatrick, Beth D ^c   Pierce, Kristen K ^c   Carmolli, Marya P ^c   Tibery, Cecilia M ^a   Grier, Palmtama L ^a   Hynes, Noreen ^a   Opert, Kari ^a   Jarvis, Adrienne P ^c   Sabundayo, Beulah P ^a   McElvany, Benjamin D ^c   Sendra, Eli A ^c   Larsson, Catherine J ^c   Jo, Matthew ^a   Lovchik, Janece M ^a   Luke, Catherine J ^b   Walsh, Mary C ^c   Fraser, Ellen A ^c   Subbarao, Kanta ^b   Whitehead, Stephen S ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

clinicaltrial; dengue vaccine; live attenuated tetravalent

Indexed keywords

DENGUE VACCINE; PLACEBO; LIVE VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFECTION PREVENTION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEROCONVERSION; SINGLE DRUG DOSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VACCINATION; VIREMIA; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS STRAIN; BLOOD; CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; NATIONAL HEALTH ORGANIZATION; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE; DENGUE VACCINES; DOUBLE-BLIND METHOD; HUMANS; IMMUNIZATION SCHEDULE; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (U.S.); PLACEBOS; UNITED STATES; VACCINES, ATTENUATED;

EID: 84985032713     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw067     Document Type: Conference Paper

References (12)

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496:504-7.
2. Barniol J, Gaczkowski R, Barbato EV, et al. Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries. BMC Infect Dis 2011; 11:106.
3. Innis BL. Antibody responses to dengue virus infection. In: Gubler DJ, Kuno G, eds. Dengue and dengue hemorrhagic fever. Cambridge: CAB International, 1997:221-43.
4. Halstead SB. Antibodies determine virulence in dengue. Ann N Y Acad Sci 2009; 1171(suppl 1):E48-56.
5. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990; 42:179-84.
6. Schwartz LM, Halloran ME, Durbin AP, Longini IM Jr. The dengue vaccine pipeline: implications for the future of dengue control. Vaccine 2015; 33:3293-8.
7. Mahoney RT, Francis DP, Frazatti-Gallina NM, et al. Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil. Vaccine 2012; 30:4892-6.
8. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981; 59:895-900.
9. Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 2011; 29:7242-50.
10. Kirkpatrick BD, Durbin AP, Pierce KK, et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis 2015; 212:702-10.
11. Durbin AP, Kirkpatrick BD, Pierce KK, et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirusnaive adults: a randomized, double-blind clinical trial. J Infect Dis 2013; 207:957-65.
12. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg 2001; 65:405-13.